Physician profile
Norma E Green
NPI 1548437544
$1,812.99
in general payments reported to CMS, 2019-2025
35 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $287 · 2021: $368 · 2022: $184 · 2023: $125 · 2024: $300 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.83 | 2021-2025 | |
| Lilly USA, LLC | $149.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $140.76 | 2019-2020 | |
| Amgen INC. | $118.85 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $100.70 | 2019-2024 | Veozah |
| Pfizer INC. | $100.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $95.07 | 2019-2024 | Breztri, Airsupra |
| Novo Nordisk INC | $77.37 | 2019-2024 | |
| Amarin Pharma, INC. | $74.32 | 2020-2021 | |
| Genentech USA, INC. | $66.34 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $63.63 | 2021-2023 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.40 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $49.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.72 | 2022 | |
| Glaxosmithkline, LLC. | $45.75 | 2019-2024 | Pediarix, Bexsero, Rotarix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.76 | 2020-2024 | Jardiance |
| Eisai INC. | $35.53 | 2020-2021 | |
| Cequr Corporation | $31.70 | 2023 | Cequr Simplicity |
| Sanofi Pasteur INC. | $27.40 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.81 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $23.53 | 2019-2021 | |
| Esperion Therapeutics, INC. | $22.15 | 2021 | |
| Axsome Therapeutics, INC. | $17.46 | 2023 | Auvelity |
| Novavax INC | $16.33 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Otsuka America Pharmaceutical, INC. | $16.10 | 2022 | |
| Abbott Laboratories | $15.76 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.12 | 2021 | |
| Electromed, INC. | $14.65 | 2025 | Smartvest |
| Sumitomo Pharma America, INC. | $14.58 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $14.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.25 | 2020 | |
| Advanced Respiratory, INC | $12.60 | 2019 | |
| Mylan Specialty L.P. | $11.79 | 2019 | |
| Csl Behring | $3.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.